HIV-derived peptide mimics

Drug Discovery Today: Technologies

Volumn 6, Issue 1-4, 2009, Pages

  Moebius, Kalle ^a   Eichler, Jutta ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 IMMUNOGLOBULIN; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY B12; NEF PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; POL PROTEIN; REV PROTEIN; TIFUVIRTIDE; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MIMICRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION;

EID: 77957860386     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2009.09.001     Document Type: Review

References (55)

1. K. Bebenek Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots J. Biol. Chem. 268 1993 10324 10334
2. N. Kaushik-Basu Peptide inhibition of HIV-1: current status and future potential BioDrugs 22 2008 161 175
3. D.R. Burton Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266 1994 1024 1027
4. P.D. Kwong Structure of an HIVgp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 1998 1998 648 659
5. R. Franke Synthetic mimetics of the CD4 binding site of HIV-1 gp120 for the design of immunogens Angew. Chem. Int. Ed. Engl. 46 2007 1253 1255
6. M.B. Zwick Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 J. Virol. 75 2001 6692 6699
7. E.O. Saphire Structure of a high-affinity 'mimotope' peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies J. Mol. Biol. 369 2007 696 709
8. M. Humbert Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma Eur. J. Immunol. 37 2007 501 515
9. A. Djordjevic The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection Curr. HIV Res. 5 2007 443 448
10. Y. Li Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants J. Virol. 80 2006 1414 1426
11. C.W-H. Zhang Expression, purification, and characterization of recombinant HIV gp140 J. Biol. Chem. 276 2001 39577 39585
12. N. Veljkovic Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease J. Pept. Res. 62 2003 158 166
13. L. Guilhaudis Solution structure of the HIV gp120 C5 domain Eur. J. Biochem. 269 2002 4860 4867
14. C. Huang Structure of a V3-containing HIV-1 gp120 core Science 310 2005 1025 1028
15. C.C. Huang Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4 Science 317 2007 1930 1934
16. O. Hartley V3: HIV's switch-hitter AIDS Res. Hum. Retroviruses 21 2005 171 189
17. A. Zvi Solution conformation of a peptide corresponding to the principal neutralizing determinant of HIV-1IIIB: a two-dimensional NMR study Biochemistry 31 1992 6972 6979
18. A. Mor Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies Biochemistry 48 2009 3288 3303
19. A.K. Dhillon Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set Acta Crystallogr. D: Biol. Crystallogr. 64 2008 792 802
20. O. Rosen Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization Biochemistry 44 2005 7250 7258
21. M. Sharon Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity Structure 11 2003 225 236
22. S.H. Ho Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques J. Virol. 81 2007 8621 8633
23. R. Barbouche Relationships between the anti-HIV V(3)-derived peptide SPC(3) and lymphocyte membrane properties involved in virus entry: SPC(3) interferes with CXCR(4) FEMS Microbiol. Lett. 183 2000 235 240
24. P.A. Galanakis NMR evidence of charge-dependent interaction between various PND V3 and CCR5 N-terminal peptides Biopolymers 92 2009 94 109
25. K. Champagne Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil J. Biol. Chem. 284 2009 3619 3627
26. J. Lu Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20) J. Virol. 78 2004 4628 4637
27. X. Bai Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure Biochemistry 47 2008 6662 6670
28. L. Martin-Carbonero Discontinuation of the clinical development of fusion inhibitor T-1249 AIDS Rev. 6 2004 61
29. J.J. Dwyer Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus Proc. Natl. Acad. Sci. U. S. A. 104 2007 12772 12777
30. B.D. Welch Potent d-peptide inhibitors of HIV-1 entry Proc. Natl. Acad. Sci. U. S. A. 104 2007 16828 16833
31. F. Gaston Development and characterization of peptidic fusion inhibitors derived from HIV-1 gp41 with partial d-amino acid substitutions ChemMedChem 4 2009 570 581
32. M. Egelhofer Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides J. Virol. 78 2004 568 575
33. S. Kim Peptide mimic of the HIV envelope gp120-gp41 interface J. Mol. Biol. 376 2008 786 797
34. M.C. Braun Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes Blood 97 2001 3531 3536
35. A. Granelli-Piperno HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation Proc. Natl. Acad. Sci. U. S. A. 101 2004 7669 7674
36. M. Bonomi Insight into the folding inhibition of the HIV-1 protease by a small peptide Biophys. J. 93 2007 2813 2821
37. M.J. Camarasa Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res. 71 2006 260 267
38. Z. Hayouka Peptides derived from HIV-1 Rev inhibit HIV-1 integrase in a shiftide mechanism Biopolymers 90 2008 481 487
39. A.D. Frankel, and J.A. Young HIV-1: fifteen proteins and an RNA Annu. Rev. Biochem. 67 1998 1 25
40. H. Porumb Circular dichroism and fluorescence of a tyrosine side-chain residue monitors the concentration-dependent equilibrium between U-shaped and coiled-coil conformations of a peptide derived from the catalytic core of HIV-1 integrase Biochim. Biophys. Acta 1699 2004 77 86
41. J. Sticht A peptide inhibitor of HIV-1 assembly in vitro Nat. Struct. Mol. Biol. 12 2005 671 677
42. A. Azizi Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques J. Immunol. 180 2008 2174 2186
43. R.M. Ferraz Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors J. Mol. Recognit. 22 2009 255 260
44. P.B. Pun Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses Int. Immunopharmacol. 9 2009 468 477
45. I.O. Gleenberg Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr) J. Mol. Biol. 369 2007 1230 1243
46. S.N. Richter Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr. Med. Chem. 16 2009 267 286
47. A. Friedler Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif J. Biol. Chem. 275 2000 23783 23789
48. S. Sandgren Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans J. Biol. Chem. 277 2002 38877 38883
49. J.P. Richard Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake J. Biol. Chem. 278 2003 585 590
50. S.B. Fonsecaa Recent advances in the use of cell-penetrating peptides for medical and biological applications Adv. Drug Deliv. Rev. 2009 10.1016/j.addr.2009.06.001
51. N. Ray, and R.W. Doms HIV-1 coreceptors and their inhibitors Curr. Top. Microbiol. Immunol. 303 2006 97 120
52. S. Fermandjian Self-association of an amphipathic helix peptide inhibitor of HIV-1 integrase assessed by electro spray ionization mass spectrometry in trifluoroethanol/water mixtures Rapid Commun. Mass Spectrom. 15 2001 320 324
53. Z. Athanassiou Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements J. Am. Chem. Soc. 126 2004 6906 6913
54. K. Moehle Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA Angew. Chem. Int. Ed. Engl. 46 2007 9101 9104
55. N.L. Mills An alpha-helical peptidomimetic inhibitor of the HIV-1 Rev-RRE interaction J. Am. Chem. Soc. 128 2006 3496 3497